Sarolaner active pharmaceutical ingredient is incorporated at unit doses from 5 mg to 120 mg in chewable immediate-release tablets intended for once-monthly oral administration to dogs. The molecule belongs to the isoxazoline class and acts by blocking arthropod GABA- and glutamate-gated chloride channels, a mechanism that does not impose a direct compression performance constraint but does place the API at a low mass fraction in the finished core. In a direct-compression sequence, the low drug load commonly below 15% w/w in a 5 mg/300 mg chewable core creates a blend uniformity burden not present in high-dose veterinary products. The API is first screened through a 600 μm sieve and geometrically pre-blended with a hydrophilic carrier such as lactose monohydrate or microcrystalline cellulose for 10 min in a low-shear tumble blender operating at 15–25 rpm. A powder pre-blend containing croscarmellose sodium 2–5% w/w and colloidal silicon dioxide 0.5–1.0% w/w is then added, followed by magnesium stearate 0.75–1.25% w/w as a final external lubricant. Over-lubrication must be controlled because a hydrophobic magnesium stearate film formed after more than 2 min total blend time can retard dissolution in 0.05 M phosphate buffer pH 6.8 containing 0.5% w/v sodium lauryl sulfate. The blend is compressed on a rotary tablet press with B-tooling at 10–20 kN; target hardness is held at 5–10 kp because higher hardness sacrifices chew texture and prolongs disintegration. Friability is kept below 1.0% according to USP <1216>, and disintegration is tested in 900 mL water at 37±2°C according to USP <701>. Content uniformity is assessed by USP <905> with an acceptance value of ≤15.0 for low-dose tablets. Tablets are packaged in aluminium/aluminium blister cavities with desiccant when packaging-area relative humidity exceeds 40% because moisture absorption by flavouring agents can soften the core and increase friability during subsequent handling.

Batch-to-batch variance observed on rotary presses primarily arises from powder segregation during hopper charging. A forced-feeder paddle speed above 30 rpm can induce density gradients, while a speed below 10 rpm may starve the die. The punch penetration depth is set to maintain a fill volume corresponding to 0.55–0.70 cm³/g tapped density of the final blend. Tablet weight is monitored by automatic weight control; drift beyond ±3.0% of target triggers rejected tablet count alarms. The chewable format also requires organoleptic masking; hydrolysed animal proteins, natural flavours, sweeteners, and citric acid or malic acid are incorporated in the extragranular phase, but these excipients increase moisture sorption, so processing tent relative humidity should remain below 50%. Published label data for commercially available sarolaner chewable tablets indicate the vehicle is food-motivated and palatable, but the quantitative formulation remains proprietary; therefore, the values above represent standard direct-compression development practice rather than a specific marketed formula.

Why Is Binder-Assisted Granulation Recommended for Dose Units Below 5 mg?

Wet granulation is introduced when the coefficient of variation of the direct-compression blend exceeds 3.0% during process validation and cannot be resolved by geometric dilution alone. For dose units below 5 mg, the sarolaner mass per tablet can fall below 2% w/w, making loss-on-wall in the blender and electrostatic adhesion to contact surfaces controlling variables. A high-shear wet granulator fitted with an impeller jacket at 20–25°C is charged with a pre-blend of sarolaner, lactose monohydrate, povidone K29–32 or hypromellose 5–15 cP as a 5–8% w/w aqueous binder solution, and croscarmellose sodium as intragranular disintegrant. The binder solution is sprayed at 10–20 g/min per kg of dry powder mass while impeller speed is held at 300–500 rpm and chopper speed at 1500–3000 rpm. Granulation endpoint is determined by impeller torque and visual progression; a target moisture of 8–12% w/w is a common endpoint for this class of low-dose veterinary granulations, though published sarolaner-specific torque curves are limited. Wet mass is discharged through a 4.0 mm screen and dried in a fluid-bed dryer with inlet air at 60–70°C and product temperature not exceeding 45°C. Target loss on drying is 1.5–2.5% w/w. The dried granulate is milled through a 0.8 mm screen; oversized returns are de-lumped rather than recycled as fines to avoid API segregation. After drying, the granules are blended with extragranular croscarmellose sodium 2–4% w/w, flavouring agents, and magnesium stearate 0.5–1.0% w/w for 3 min. The final blend is compressed at 8–15 kN to a hardness of 5–8 kp; the lower hardness range is required because granulated chewable tablets can densify under high pressure and lose the soft mouthfeel required for voluntary ingestion.

A critical failure mode in transfer from high-shear granulator to fluid-bed dryer is the formation of hard lumps due to local overwetting. If spray rate exceeds the powder absorption capacity of the formulation, the wet mass can reach a torque overshoot; the resulting dense granules may require additional milling passes and generate fines below 75 μm. Fines below 10% w/w are generally tolerated, but levels above 25% w/w cause die-filling variability and punch sticking. The granulation process is validated by sampling at top, middle, and bottom of the fluid-bed bowl for moisture, particle-size distribution, and bulk density. Acceptance limits should be tied to the tablet compression response: loose bulk density 0.45–0.55 g/mL, tapped bulk density 0.60–0.70 g/mL, and Carr index 20–25% support sufficient flow. Sieve analysis should show D10 >75 μm, D50 200–400 μm, and D90 <1000 μm; published data for sarolaner granule particle-size distribution are limited, so the batch record must adopt limits from actual pilot-scale runs. The assay and related substances method is established as a stability-indicating HPLC procedure with UV detection and a C18 stationary phase; wavelength selection is derived from the API UV maximum, and specificity is validated against forced degradation products according to ICH Q2(R1). Impurity reporting, identification, and qualification thresholds follow ICH Q3A and ICH Q3B based on maximum daily dose.

Combination products that contain sarolaner with moxidectin and pyrantel pamoate introduce a segregation and compatibility matrix not found in single-active tablets. The high mass of pyrantel pamoate relative to sarolaner and moxidectin requires the same low-dose blending controls as direct compression, but the dominant particle-size difference between pyrantel pamoate suspension-grade raw material and micronized isoxazoline makes unagglomerated powder blends physically unstable. Therefore, the low-dose actives are frequently pre-granulated with a portion of the filler or with povidone binder, while pyrantel pamoate is granulated separately with a low-moisture binder or added as a compressible granulation. The separate granulations are then blended in a low-shear mixer for 10–15 min before lubrication. This processing choice reduces physical contact between the large pyrantel pamoate particles and the low-dose actives and allows pH and moisture controls specific to each granulation. Pyrantel pamoate stability is influenced by moisture and pH stress, and moxidectin requires oxidative stress control during wet processing; the granulating fluid is therefore buffered to pH 5.5–6.8 and the wet mass is dried promptly. Each active must be sampled for content uniformity in the mixer at 10, 20, and 30 min; a stratified sampling plan with 9 positions is used during validation. Release testing includes HPLC assay for sarolaner, moxidectin, and pyrantel; the analytical method is validated for specificity against each degradation product per ICH Q2(R1). Disintegration and dissolution are run on the finished chewable tablet, with a two-stage dissolution profile in 0.1 M HCl and then pH 6.8 buffer containing 0.5% sodium lauryl sulfate because sarolaner solubility is pH-dependent and low in aqueous media.

Cleaning validation is burdensome because sarolaner and moxidectin are active at milligram levels; carryover below 10 ppm or 0.1% of the minimum daily dose is normally adopted in multi-product facilities. High-performance liquid chromatography with tandem mass spectrometry is used for swab and rinse sampling, with swab recovery validated at 70–120%. The production sequence should run the lowest-dose active first or dedicate contact parts after campaign changeover. The commercial once-monthly triple combination tablet is supplied in child-resistant blister packaging, and quality release includes identity, assay, water activity, and microbial enumeration per USP <2021> and USP <2022> if flavouring proteins are present. Published formulation ratios for the marketed triple product are proprietary; the statements here reflect industrial development practice for low-dose combination solid oral dosage forms.

When a Non-Aqueous Injectable System Is Engineered for Clinic Use

Parenteral administration of sarolaner is not established in commercial label use; however, the API can be evaluated for injectable solution or suspension only with non-aqueous carriers because aqueous solubility is extremely low. A practical formulation screen includes benzyl alcohol, ethyl oleate, medium-chain triglycerides, and a co-solvent such as dimethyl sulfoxide or N-methyl-2-pyrrolidone, but each has injection-site tolerability limits. For a 10–20 mg/mL target concentration, the API may be dissolved in a non-aqueous solvent system and then filtered through 0.22 μm hydrophobic PVDF membrane; if a suspension is developed, particle size is reduced by wet milling to D90 <10 μm to ensure injectability through 21–23-gauge needles. The carrier must be selected with reference to ICH Q3C residual solvent limits, because N-methyl-2-pyrrolidone is a Class 2 solvent with a defined permitted daily exposure; dimethyl sulfoxide is similarly controlled under the site residual solvent risk assessment even where monograph allowances vary. Viscosity at 25°C is measured by USP <912> or a cone-plate rheometer; values below 100 mPa·s are preferred for injection, but long-acting depot products may exceed this. Sterility testing according to USP <71> is mandatory; for a sterile injectable, the fill line is operated in an ISO Class 5 environment under ISO 14644-1, and the final container is loaded chilled or with oxygen headspace below 2.0% if oxidation is observed during ICH Q1A(R2) stability. Bacterial endotoxin limits are calculated using USP <85> based on maximum dose: endotoxin limit = K/M, where K is 5 EU/kg for parenteral products and M is the maximum dose per kg; this yields a typical limit of not more than 5 EU/kg per administration. Particulate matter is monitored by USP <790> and USP <788>; for small-volume injections, the container content is passed only if no visible particles are observed and subvisible counts meet 6000 particles ≥10 μm and 600 particles ≥25 μm per container.

Injectable development of sarolaner faces a solubility-permeation conflict. The molecule is highly plasma protein bound in vivo and distributes extensively; formulation as a clear solution may require high concentrations of co-solvents that cause haemolysis or injection-site pain. A water-free vehicle can shift tonicity and irritate muscle tissue; isotonicity measured by USP <785> is not applicable to non-aqueous carriers, but pH and conductivity of residual water are monitored in-process. Terminal sterilisation is preferred over aseptic filtration when the carrier tolerates heat, but autoclaving at 121°C for 15 min may accelerate degradation of the isoxazoline ring. Aseptic filtration through a sterilising-grade membrane remains the standard for non-aqueous small-volume injections, and filter compatibility is confirmed by a forward-flow diffusion integrity test rather than bubble point alone. If a suspension is developed, syringeability and resuspendability are evaluated by a calibrated force gauge; ejection force below 25 N is normally required for manual injection. Published data for the specific injectable bioavailability and irritation profile of sarolaner is limited; the conditions above are generic parenteral engineering criteria rather than a licensed commercial formulation.

Lipid-based hard capsule systems are evaluated when a facility cannot achieve the palatability profile of chewable tablets or when a taste-masked multiparticulate is required for small companion animals. In a hard gelatin or HPMC capsule, sarolaner is dissolved in a lipid carrier made of medium-chain triglycerides and a surfactant such as PEG-40 hydrogenated castor oil or a poloxamer, then filled under heated conditions of 30–40°C. The fill mass is set by dose; the filling pump is calibrated gravimetrically every 15 min, and seal integrity of banded capsules is tested by leak detection at 0.10–0.15 bar vacuum. Dissolution of the filled capsule is evaluated in 900 mL of 0.1 M HCl with 1.0% w/v sodium lauryl sulfate and in pH 6.8 buffer, using sinkers and paddle speed 75 rpm according to a modified USP <711> method. Self-emulsifying and self-microemulsifying systems require droplet size measurement by dynamic light scattering; a median droplet size below 200 nm is common for enhanced dispersion, but published sarolaner capsule-specific data is limited. The capsule shell moisture content must be maintained at 13–16% for gelatin and 4–6% for HPMC to prevent brittleness; storage at 40°C and 75% RH for 6 months under ICH Q1A(R2) accelerated conditions is used to define shelf life.

A distinct process risk in lipid filling is capsule body deformation when the fill mass is above 85% of the shell volume. The filling machine needs an independent cold-jacket reservoir at 10–15°C to maintain the lipid excipient in a semi-solid state and to reduce thread fining during pump discharge. Fill weight uniformity is recorded by in-line checkweighers; for a 10 mg dose fill weight of 150 mg, rejection limits of ±2.0% are typical. Cross-contamination is controlled because the same filling suite may be used for other lipid-based animal health products. Cleaning validation with oily excipients requires heated detergent solution above the cloud point of the surfactant, and swab extraction recovery for sarolaner from stainless steel is determined by HPLC-MS/MS. If enteric protection is needed, the filled capsules are coated in a pan coater with a pH-sensitive methacrylic acid copolymer; coating weight gain of 5–8% w/w is typical and is tested for gastric resistance in 0.1 M HCl for 2 h without leakage, followed by release in pH 6.8 phosphate buffer. No commercial enteric sarolaner capsule is referenced; this is a development route.

Sachet-Loaded Granule Intermediates Under Humidity and Pack Integrity Stress

Sarolaner granulate intended for sachet packaging or downstream compression is produced as a dry intermediate with narrow particle-size distribution and low water activity. The granulate is filled into aluminium-laminate sachets containing 50 g to 300 g of finished granules, although small unit-dose sachets of 1 g to 10 g are used for single-animal dosing in some development programs. The product contact relative humidity during filling must be kept below 30% to avoid agglomeration; the fill room is maintained at 18–24°C with dew point below 8°C. Sieve analysis after filling should preserve D10 >75 μm, D50 200–500 μm, and D90 <1000 μm, with fines below 10% w/w. Water activity is measured by chilled-mirror dew point technique at 25°C and should remain below 0.6 to limit microbial growth in nonsterile granulate per USP <1112>. Pack integrity is checked by vacuum decay and dye penetration; the seal must withstand 0.1 bar for 30 s without visible dye ingress. Leakers are quarantined because moisture-labile flavouring agents and the lipophilic API can partition into softened sealing film. Dose accuracy from sachet is verified by simulated in-feed mixing: the granulate is mixed with 1 kg of dry dog food in a paddle mixer at 50 rpm for 5 min, and samples are assayed at three locations to confirm relative standard deviation below 3.0% prior to release. Published sarolaner-specific sachet stability data is limited, so bracketing and matrixing protocols under ICH Q1A(R2) are used.

The granule intermediate can be compacted, milled, and filled into capsules or compressed into tablets. The mechanical stress of sachet filling is lower than tablet compression, so the granule crumble strength may be reduced to 20–50 g to improve dispersibility. The bulk density is adjusted to 0.40–0.55 g/mL; very-low-density granules below 0.35 g/mL create static charge during filling, while very-high-density granules above 0.70 g/mL may resist dispersion in feed. Packaging density and headspace are specified as a ratio; the sachet fill volume should not exceed 70% of pouch internal volume to permit headspace nitrogen flushing. Residual oxygen below 2.0% is achieved by triple flushing with nitrogen and is verified by an oxygen analyser using a zirconia cell. The finished granulate is tested for assay, related substances, water activity, residual solvents per USP <467>, and elemental impurities per USP <232> and USP <233> with ICH Q3D. The elemental impurities analysis is required because excipients derived from mineral sources may contribute lead, arsenic, or cadmium; the API vendor supplies a statement of the elemental impurity risk assessment under ICH Q3D.